CAR-T Meeting 2021 | Universal “off-the-shelf” CAR T-cells from iPSCs

Current CAR T-cell approaches must be generated on a custom-made basis, limiting the general use of this promising immunotherapy. Alexandros Nianias, MSc, Amsterdam University Medical Centers, Amsterdam, Netherlands, shares findings from a study designed to develop CAR-engineered T-cell-derived induced pluripotent stem cells (TiPSC) with adaptive immune features that could be universally applicable. The strategy evaluated for the generation of non-allo-reactive and non-immunogenic TiPSC-derived CAR T-cells supports the development of universal “off-the-shelf” CAR T-cells in the future. This interview took place during the 3rd European CAR T-cell Meeting.